Versor Investments LP Purchases New Stake in Elanco Animal Health Incorporated (NYSE:ELAN)

Versor Investments LP purchased a new stake in Elanco Animal Health Incorporated (NYSE:ELAN) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 25,900 shares of the company’s stock, valued at approximately $380,000.

Several other hedge funds have also added to or reduced their stakes in the company. 180 Wealth Advisors LLC boosted its holdings in Elanco Animal Health by 3.6% in the second quarter. 180 Wealth Advisors LLC now owns 25,716 shares of the company’s stock valued at $352,000 after acquiring an additional 893 shares during the last quarter. HBK Sorce Advisory LLC boosted its holdings in Elanco Animal Health by 9.4% in the second quarter. HBK Sorce Advisory LLC now owns 12,920 shares of the company’s stock valued at $186,000 after acquiring an additional 1,107 shares during the last quarter. Atomi Financial Group Inc. boosted its holdings in Elanco Animal Health by 11.1% in the second quarter. Atomi Financial Group Inc. now owns 12,260 shares of the company’s stock valued at $177,000 after acquiring an additional 1,221 shares during the last quarter. Keene & Associates Inc. boosted its holdings in Elanco Animal Health by 5.7% in the third quarter. Keene & Associates Inc. now owns 22,945 shares of the company’s stock valued at $337,000 after acquiring an additional 1,240 shares during the last quarter. Finally, Resonant Capital Advisors LLC boosted its holdings in Elanco Animal Health by 5.0% in the second quarter. Resonant Capital Advisors LLC now owns 27,325 shares of the company’s stock valued at $394,000 after acquiring an additional 1,306 shares during the last quarter. Institutional investors own 97.48% of the company’s stock.

Insider Activity at Elanco Animal Health

In other news, Director Michael J. Harrington bought 3,500 shares of the company’s stock in a transaction that occurred on Thursday, August 22nd. The shares were acquired at an average price of $14.85 per share, with a total value of $51,975.00. Following the transaction, the director now owns 81,094 shares in the company, valued at $1,204,245.90. This represents a 4.51 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.57% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

ELAN has been the topic of several recent research reports. Morgan Stanley cut Elanco Animal Health from an “overweight” rating to an “equal weight” rating and decreased their price target for the company from $17.00 to $15.00 in a report on Thursday, September 19th. Barclays increased their target price on Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, November 8th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $20.00 target price on shares of Elanco Animal Health in a research note on Thursday, September 19th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $17.14.

Elanco Animal Health Trading Down 1.1 %

NYSE ELAN opened at $14.04 on Friday. The firm has a market cap of $6.94 billion, a P/E ratio of 35.10, a P/E/G ratio of 1.48 and a beta of 1.41. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The stock’s 50-day moving average is $13.84 and its 200-day moving average is $14.75. Elanco Animal Health Incorporated has a one year low of $11.20 and a one year high of $18.80.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.01. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The company had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.04 billion. During the same quarter last year, the firm posted $0.18 earnings per share. Elanco Animal Health’s revenue was down 3.6% compared to the same quarter last year. Sell-side analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.